Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,879 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Diagnostic dyspraxia and frontal syndrome].
Donnet A, Schmitt A, Poncet M. Donnet A, et al. Among authors: schmitt a. Rev Neurol (Paris). 1998 May;154(4):334-8. Rev Neurol (Paris). 1998. PMID: 9773062 French.
Pure left hemianacousia: clinical and neurophysiological study.
Donnet A, Farnarier G, Schmitt A, Graziani N, Grisoli F. Donnet A, et al. Among authors: schmitt a. Clin Electroencephalogr. 1993 Apr;24(2):85-8. doi: 10.1177/155005949302400209. Clin Electroencephalogr. 1993. PMID: 8500253
Primary central nervous system lymphoma of the spinal cord: A LOC network cohort study.
Valyraki N, Ahle G, Tabouret E, Houot R, Jardin F, Ghesquières H, Schmitt A, Paillassa J, Choquet S, Soussain C, Ursu R, Nichelli L, Legarff-Tavernier M, Mathon B, Rozenblum L, Mokhtari K, Hoang-Xuan K, Houillier C. Valyraki N, et al. Among authors: schmitt a. Rev Neurol (Paris). 2024 Dec 19:S0035-3787(24)00662-3. doi: 10.1016/j.neurol.2024.11.003. Online ahead of print. Rev Neurol (Paris). 2024. PMID: 39706697
Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcSé-crizotinib trial.
Brugières L, Cozic N, Houot R, Rigaud C, Sibon D, Arfi-Rouche J, Bories P, Cottereau AS, Delmer A, Ducassou S, Garnier N, Lamant L, Leruste A, Millot F, Moalla S, Morschhauser F, Nolla M, Pagnier A, Reguerre Y, Renaud L, Schmitt A, Simonin M, Verschuur A, Hoog Labouret N, Mahier Ait Oukhatar C, Vassal G. Brugières L, et al. Among authors: schmitt a. Eur J Cancer. 2023 Sep;191:112984. doi: 10.1016/j.ejca.2023.112984. Epub 2023 Jul 17. Eur J Cancer. 2023. PMID: 37549532 Free article.
Safety and efficacy of trifluridine/tipiracil +/- bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial.
Thibaudin M, Roussot N, Burlot C, Schmitt A, Vincent J, Tharin Z, Bengrine L, Bellio H, Bertaut A, Hampe L, Daumoine S, Rederstorff E, Peroz M, Huppe T, Derangère V, Rageot D, Simard J, Truntzer C, Fumet JD, Ghiringhelli F. Thibaudin M, et al. Among authors: schmitt a. Signal Transduct Target Ther. 2025 Jan 17;10(1):22. doi: 10.1038/s41392-024-02116-4. Signal Transduct Target Ther. 2025. PMID: 39820336 Clinical Trial.
1,879 results